87 related articles for article (PubMed ID: 31630958)
1. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts.
Maccarana M; Tykesson E; Pera EM; Gouignard N; Fang J; Malmström A; Ghiselli G; Li JP
Glycobiology; 2021 Nov; 31(10):1319-1329. PubMed ID: 34192316
[TBL] [Abstract][Full Text] [Related]
3. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Harmatz P; Giugliani R; Martins AM; Hamazaki T; Kubo T; Kira R; Minami K; Ikeda T; Moriuchi H; Kawashima S; Takasao N; So S; Sonoda H; Hirato T; Tanizawa K; Schmidt M; Sato Y
Mol Ther; 2024 Mar; 32(3):609-618. PubMed ID: 38204164
[TBL] [Abstract][Full Text] [Related]
4. Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
Lau YK; Peck SH; Arginteanu T; Wu M; Lin M; Shore EM; Klein PS; Casal ML; Smith LJ
Bone; 2022 Jan; 154():116237. PubMed ID: 34695616
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
Lawrence R; Brown JR; Al-Mafraji K; Lamanna WC; Beitel JR; Boons GJ; Esko JD; Crawford BE
Nat Chem Biol; 2012 Jan; 8(2):197-204. PubMed ID: 22231271
[TBL] [Abstract][Full Text] [Related]
6. Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.
Tong W; Dwyer CA; Thacker BE; Glass CA; Brown JR; Hamill K; Moremen KW; Sarrazin S; Gordts PLSM; Dozier LE; Patrick GN; Tor Y; Esko JD
Mol Ther; 2017 Dec; 25(12):2743-2752. PubMed ID: 28958576
[TBL] [Abstract][Full Text] [Related]
7. A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I.
Le SQ; Kan SH; Clarke D; Sanghez V; Egeland M; Vondrak KN; Doherty TM; Vera MU; Iacovino M; Cooper JD; Sands MS; Dickson PI
Mol Ther Methods Clin Dev; 2018 Mar; 8():42-51. PubMed ID: 29159202
[TBL] [Abstract][Full Text] [Related]
8. Hurler Syndrome Glycosaminoglycans Decrease in Cerebrospinal Fluid without Brain-Targeted Therapy.
Lund TC; Braunlin E; Polgreen LE; Gupta AO; Orchard PJ; Eisengart JB
Ann Neurol; 2023 Dec; 94(6):1182-1186. PubMed ID: 37679306
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis Type I: The Importance of Early Diagnosis for Adequate Treatment.
Diogo R; Diogo L; Serra R; Almeida J; Oliveira A
Cureus; 2023 Dec; 15(12):e50595. PubMed ID: 38222174
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Total Human Urinary Glycosaminoglycan Disaccharides by Liquid Chromatography-Tandem Mass Spectrometry.
Sun X; Li L; Overdier KH; Ammons LA; Douglas IS; Burlew CC; Zhang F; Schmidt EP; Chi L; Linhardt RJ
Anal Chem; 2015 Jun; 87(12):6220-7. PubMed ID: 26005898
[TBL] [Abstract][Full Text] [Related]
11. Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I.
Tolar J; Orchard PJ; Key NS; Blazar BR
J Thromb Haemost; 2008 May; 6(5):893-5. PubMed ID: 18315551
[No Abstract] [Full Text] [Related]
12. Hepatomegaly and Splenomegaly: An Approach to the Diagnosis of Lysosomal Storage Diseases.
Jerves Serrano T; Gold J; Cooper JA; Church HJ; Tylee KL; Wu HY; Kim SY; Stepien KM
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592278
[TBL] [Abstract][Full Text] [Related]
13. Biochemical signatures of disease severity in multiple sulfatase deficiency.
Adang LA; Mowafy S; Herbst ZM; Zhou Z; Schlotawa L; Radhakrishnan K; Bentley B; Pham V; Yu E; Pillai NR; Orchard PJ; De Castro M; Vanderver A; Pasquali M; Gelb MH; Ahrens-Nicklas RC
J Inherit Metab Dis; 2024 Mar; 47(2):374-386. PubMed ID: 37870986
[TBL] [Abstract][Full Text] [Related]
14. A glycomic workflow for LC-MS/MS analysis of urine glycosaminoglycan biomarkers in mucopolysaccharidoses.
Nilsson J; Persson A; Vorontsov E; Nikpour M; Noborn F; Larson G; Blomqvist M
Glycoconj J; 2023 Oct; 40(5):523-540. PubMed ID: 37462780
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference?
Orchard PJ; Gupta AO; Eisengart JB; Polgreen LE; Pollard LM; Braunlin E; Pasquali M; Lund TC
Blood Adv; 2022 Dec; 6(23):6023-6027. PubMed ID: 35476057
[No Abstract] [Full Text] [Related]
16. Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.
Vera MU; Le SQ; Victoroff A; Passage MB; Brown JR; Crawford BE; Polgreen LE; Chen AH; Dickson PI
Mol Genet Metab; 2020 Feb; 129(2):91-97. PubMed ID: 31630958
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
